PMID- 9241076
OWN - NLM
STAT- MEDLINE
DCOM- 19970812
LR  - 20220409
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 80
IP  - 3
DP  - 1997 Aug 1
TI  - Expression of interleukin-1beta in human breast carcinoma.
PG  - 421-34
AB  - BACKGROUND: Interleukin 1beta (IL-1beta) is a multifunctional cytokine that 
      up-regulates the inflammatory response. It is not known whether IL-1beta plays a 
      major role in human malignancy. To determine whether IL-1beta might be involved 
      in breast carcinoma progression, the authors measured the IL-1beta content in 
      tissue extracts from >200 invasive breast carcinomas and smaller numbers of 
      ductal carcinoma in situ (DCIS) and benign lesions. METHODS: IL-1beta content was 
      measured by an enzyme-linked immunoadsorbent assay and analyzed to determine 
      whether these values were correlated with the contents of scatter factor (SF) (an 
      invasogenic and angiogenic cytokine), von Willebrand's factor (VWF) (a marker of 
      endothelium), thrombospondin-1 (TSP1) (an antiadhesive and antiangiogenic 
      glycoprotein), and tumor necrosis factor-alpha (TNF alpha) (another 
      proinflammatory cytokine). Studies were also performed to determine whether 
      IL-1beta content was correlated with other pathologic and immunochemical 
      variables that have been utilized or proposed as prognostic indicators for breast 
      carcinoma. RESULTS: The most important findings of these studies were: 1) 
      immunoreactive IL-1beta was detected in approximately 90% of invasive breast 
      carcinomas; 2) IL-1beta levels were significantly higher in invasive carcinomas 
      than in a group of DCIS and benign lesions; 3) high IL-1beta content in invasive 
      carcinomas was significantly associated with higher contents of SF, VWF, and 
      TSP1, but not TNF alpha; and 4) there was a trend toward higher IL-1beta content 
      in invasive carcinomas with a group of other parameters that suggest a 
      biologically more aggressive tumor (estrogen receptor negativity, high tumor 
      grade, p53 positivity, and bcl-2 negativity); and the proportion of invasive 
      tumors with these characteristics was significantly increased in a subgroup of 
      tumors having very high IL-1beta content. The authors also found a correlation 
      between high IL-1beta content and CD68 positivity, suggesting that macrophages 
      may account for some of the IL-1beta present in human breast carcinoma tissue. 
      CONCLUSIONS: These findings suggest that significant titers of IL-1beta are 
      present within the microenvironment of most breast carcinomas and that a high 
      IL-1beta content is often associated with tumor invasiveness and with other 
      pathologic features suggestive of an aggressive tumor biology.
FAU - Jin, L
AU  - Jin L
AD  - Department of Radiation Oncology, Long Island Jewish Medical Center, The Long 
      Island Campus for Albert Einstein College of Medicine, New Hyde Park, New York 
      11040, USA.
FAU - Yuan, R Q
AU  - Yuan RQ
FAU - Fuchs, A
AU  - Fuchs A
FAU - Yao, Y
AU  - Yao Y
FAU - Joseph, A
AU  - Joseph A
FAU - Schwall, R
AU  - Schwall R
FAU - Schnitt, S J
AU  - Schnitt SJ
FAU - Guida, A
AU  - Guida A
FAU - Hastings, H M
AU  - Hastings HM
FAU - Andres, J
AU  - Andres J
FAU - Turkel, G
AU  - Turkel G
FAU - Polverini, P J
AU  - Polverini PJ
FAU - Goldberg, I D
AU  - Goldberg ID
FAU - Rosen, E M
AU  - Rosen EM
LA  - eng
GR  - CA-64416/CA/NCI NIH HHS/United States
GR  - CA-64869/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-1)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (von Willebrand Factor)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers/analysis
MH  - Breast Neoplasms/*metabolism/pathology
MH  - Carcinoma in Situ/*metabolism/pathology
MH  - Carcinoma, Ductal, Breast/*metabolism/pathology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Hepatocyte Growth Factor/metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Interleukin-1/*biosynthesis
MH  - Lymphatic Metastasis
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-2/metabolism
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - von Willebrand Factor/metabolism
EDAT- 1997/08/01 00:00
MHDA- 2000/06/20 09:00
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1997/08/01 00:00 [entrez]
AID - 10.1002/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z [pii]
AID - 10.1002/(sici)1097-0142(19970801)80:3<421::aid-cncr10>3.0.co;2-z [doi]
PST - ppublish
SO  - Cancer. 1997 Aug 1;80(3):421-34. doi: 
      10.1002/(sici)1097-0142(19970801)80:3<421::aid-cncr10>3.0.co;2-z.